Di seguito è disponibile un documento dell'Organizzazione Mondiale della Sanità che ha stilato un piano di azione quinquennale per combattere la tubercolosi multiresistente.

Executive Summary of Consolidated action plan to prevent and combat multidrug- and extensively drug-resistant tuberculosis in the WHO European Region 2011–2015

In response to the alarming problem of multidrug- and extensively drug-resistant tuberculosis (M/XDR-TB) in the WHO European Region, the Regional Director has established a Special Project to Prevent and Combat M/XDR-TB in the Region. In order to scale up a comprehensive response and to prevent and control M/XDR-TB, a consolidated action plan has been developed for 2011–2015 for the 53 Member States, the WHO Regional Office for Europe and partners. The Consolidated Action Plan to Prevent and Control M/XDR-TB in the WHO European Region 2011–2015 has six strategic directions and seven areas of intervention. The strategic directions are cross-cutting and are designed to safeguard the values of the Health 2020 strategy and highlight the corporate priorities of the WHO European Region. The areas of intervention are aligned with the Global Plan to Stop TB 2011–2015 and include the same targets as set by the Global Plan and World Health Assembly resolution WHA62.15, namely to provide universal access to diagnosis and treatment of MDR-TB.

A more detailed version of the Consolidated Action Plan is being developed, which will serve national TB and communicable disease programmes and divisions, and technical and bilateral agencies, as an operational roadmap for implementation of activities. The WHO Regional Office has assisted Member States in the WHO European Region with a high MDR-TB burden to develop national MDR-TB response plans based on the Beijing Commitment. The Consolidated Action Plan will guide Member States in further elaboration and integration of national MDR-TB response plans in their national TB and/or national health strategies and plans.

With implementation of the Consolidated Action Plan, the emergence of 110 000 new MDR-TB patients and 5200 XDR-TB patients would be averted, an estimated 310 000 MDR-TB patients would be diagnosed and at least 230 000 of them would be successfully treated hence interrupting the transmission of MDR-TB; 122 000 lives and US$ 1.5 billion would be saved. (Detailed modelling of the cost of implementation and the savings to be made by cutting transmission is being fine-tuned and will be ready in May 2011.)